Romanian stock indices close mixed in higher turnover
Bulgarian stock indices retreat amid higher turnover
Bulgaria to collect 2.1 bln euro for energy security fund in 2023
OECD downgrades Slovenia's 2023 GDP growth f'cast to 1.4%
Rompetrol Rafinare invests $6.5 mln in storage tanks overhaul
Oct 23, 2009 14:53 EEST
BELGRADE (Serbia), October 23 (SeeNews) – U.S. pharmaceutical company Eli Lilly plans to enter the Serbian market soon, local broadcaster b92 reported on Friday.
“In these challenging times we have serious intentions to be present in Serbia by investing and opening a new office for Lilly, which is one of 10 biggest pharmaceutical companies in the world,” b92 (www.b92.net) reported, quoting Philippe Prufer, Eli Lilly vice president and area director of European mid-size as well as central and eastern European markets, as telling a news conference in Belgrade.
The company executive did not provide a figure or a timeframe for the planned investment.
Eli Lilly already works with local partners in Serbia, offering a limited range of medical products, Prufer said.
The company had a successful cooperation with Serbia’s largest drug maker Galenika in the 1990s and has had business relations with the local unit of PharmaSwiss since 2005 and plans to further develop its local partnerships, Prufer added.
Eli Lilly, headquartered in Indianapolis, Indiana, employs approximately 39,140 worldwide. It runs research and development facilities in eight countries and manufacturing plants in 13 countries and markets its products in 143 countries.
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options